CytomX Therapeutics (CTMX) said Wednesday the US Food and Drug Administration has cleared the investigational new drug application for CX-904 being...
CytomX Therapeutics (CTMX) has an average rating of buy and price targets ranging from $7 to $16, according to analysts polled by Capital IQ. (MT Newswires...
CytomX Therapeutics (CTMX) has an average rating of outperform and price targets ranging from $7 to $16, according to analysts polled by Capital IQ. (MT...
(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
| Address | 151 Oyster Point Boulevard South San Francisco, California 94080-1913 |
| Phone | +1.605.515.3185 |
| Number of Employees | 137 |
| Recent SEC Filing | 01/10/2022 8-K |
| Chairman, President & Chief Executive Officer | Sean A. McCarthy |
| Chief Financial Officer & Senior Vice President | Carlos E. Campoy |
| Senior Vice President & Head-Research | Marcia P. Belvin |
| Chief Medical Officer & Senior Vice President | Alison L. Hannah |
| Price Open | $4.12 |
| Previous Close | $4.16 |
| 52 Week Range | $3.67 - 10.05 |
| Market Capitalization | $279.9 M |
| Shares Outstanding | 65.2 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 02/23/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$1.21 |
| Beta vs. S&P 500 | N/A |
| Revenue | $59.5 M |
| Net Profit Margin | -108.85% |
| Return on Equity | -65.76% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
